Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  PI3K / Akt / mTOR >  PI3K inhibitor >  NVP-BGT226

NVP-BGT226

Basic information Safety Supplier Related

NVP-BGT226 Basic information

Product Name:
NVP-BGT226
Synonyms:
  • 8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one Maleic acid
  • BGT-226 maleate
  • BGT226 (NVP-BGT226)
  • BGT226 (NVP-BGT226);NVP-BGT226
  • 8-(6-Methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo
  • 1-(3-(Trifluoromethyl)-4-(piperazin-1-yl)phenyl)-8-(6-methoxypyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-one maleic acid salt
  • BGT226
  • NVP-BGT226
CAS:
1245537-68-1
MF:
C28H25F3N6O2.C4H4O4
MW:
650.6044696
Product Categories:
  • Akt
  • mTOR
  • PI3K
  • PI3K/Akt/mTOR
  • Inhibitors
Mol File:
1245537-68-1.mol
More
Less

NVP-BGT226 Chemical Properties

Melting point:
>215°C (dec.)
storage temp. 
Hygroscopic, -20°C Freezer, Under inert atmosphere
solubility 
DMSO (Slightly)
form 
Solid
color 
White to Pale Yellow
More
Less

NVP-BGT226 Usage And Synthesis

Uses

BGT 226 is a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin (PI3K/mTOR ) dual inhibitor which has shown to be effective with gefitinib in epidermal growth factor receptor (EGFR) inhibitor-sensitive non-small cell lung cancer (NSCLC) therapy.

Definition

ChEBI: BGT226 is the maleate salt of 8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one. A dual PI3K/mTOR inhibitor. It has a role as an antineoplastic agent, a mTOR inhibitor and an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor. It contains a BGT226(1+).

in vivo

BGT226 (2.5 and 5 mg/kg; oral administration for 21 days in male athymic mice) causes 34.7% and 76.1% reduction of the tumor growth on day 21 compared with control[2].

Animal Model:Male athymic mice (strain BALB/cAnN.Cg-Foxn1nu/CrlNarl) with FaDu cell xenografted mouse model[2]
Dosage:2.5 and 5 mg/kg
Administration:Oral administration; 21 days
Result:Caused 34.7% and 76.1% reduction of the tumor growth.

target

PI3Kα

IC 50

PI3Kα: 4 nM (IC50); PI3Kγ: 38 nM (IC50); PI3Kβ: 63 nM (IC50); mTOR; Autophagy

NVP-BGT226Supplier

Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
Jinan Trio PharmaTech Co., Ltd.
Tel
0531-88811783
Email
sales@trio-pharmatech.com
Dalian Meilun Biotech Co., Ltd.
Tel
0411-62910999 13889544652
Email
sales@meilune.com
NCE Biomedical Co.,Ltd.
Tel
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
More
Less

NVP-BGT226(1245537-68-1)Related Product Information